AmirAli Talasaz sold $11M of GH
Co-Chief Executive Officer at Guardant Health, Inc.. 100,000 shares at an average of $105.05, traded Dec 8, 2025, filed Dec 10, 2025.
Score components
- +25RoleCEO
- +25Trade size$10.5M at market
- +10Share of holdings soldSold 46% of holdings
- +15Cluster10 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001753159-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 8, 2025 | JOther Common Stockindirect: Shares held by Talasaz Investments, L.P. | -387,946 | $0.00 | $0 | 82,854 | Dec 10, 2025 |
| Dec 8, 2025 | JOther Common Stockindirect: Shares held by AmirAli Talasaz 2018 Children's Remainder Trust, Dated 9/25/2018 | +193,973 | $0.00 | $0 | 218,223 | Dec 10, 2025 |
| Dec 8, 2025 | JOther Common Stockindirect: Shares held by Maryam Eskandari 2018 Children's Remainder Trust, Dated 9/25/2018 | +193,973 | $0.00 | $0 | 218,223 | Dec 10, 2025 |
| Dec 8, 2025 | SOpen-market sale Common Stockindirect: Shares held by AmirAli Talasaz 2018 Children's Remainder Trust, Dated 9/25/2018 | -15,000 | $104.21 | $1.6M | 203,223 | Dec 10, 2025 |
| Dec 8, 2025 | SOpen-market sale Common Stockindirect: Shares held by AmirAli Talasaz 2018 Children's Remainder Trust, Dated 9/25/2018 | -30,760 | $105.34 | $3.2M | 172,463 | Dec 10, 2025 |
| Dec 8, 2025 | SOpen-market sale Common Stockindirect: Shares held by AmirAli Talasaz 2018 Children's Remainder Trust, Dated 9/25/2018 | -4,240 | $106.00 | $449k | 168,223 | Dec 10, 2025 |
| Dec 8, 2025 | SOpen-market sale Common Stockindirect: Shares held by Maryam Eskandari 2018 Children's Remainder Trust, Dated 9/25/2018 | -15,000 | $104.21 | $1.6M | 203,223 | Dec 10, 2025 |
| Dec 8, 2025 | SOpen-market sale Common Stockindirect: Shares held by Maryam Eskandari 2018 Children's Remainder Trust, Dated 9/25/2018 | -30,760 | $105.34 | $3.2M | 172,463 | Dec 10, 2025 |
| Dec 8, 2025 | SOpen-market sale Common Stockindirect: Shares held by Maryam Eskandari 2018 Children's Remainder Trust, Dated 9/25/2018 | -4,240 | $106.00 | $449k | 168,223 | Dec 10, 2025 |
Related signals
Other insiders at Guardant Health, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 41Moderate | Guardant Health, Inc. | Alex M Azar II director | $145k 826 shares | -50% | |
| 55Moderate | Guardant Health, Inc. | Darya Chudova Chief Technology Officer | $1.4M 7,738 shares | -10% | |
| 65Notable | Guardant Health, Inc. | Steve E. Krognes director | $1.2M 6,674 shares | -46% | |
| 0Weak | Guardant Health, Inc. | Musa Tariq director | $20k 116 shares | -1% | |
| 50Moderate | Guardant Health, Inc. | Kumud Kalia Chief Information Officer | $632k 4,000 shares | -9% | |
| 10Weak | Guardant Health, Inc. | Musa Tariq director | $12k 116 shares | -1% | |
| 59Moderate | Guardant Health, Inc. | Darya Chudova Chief Technology Officer | $567k 5,451 shares | -44% | |
| 65Notable | Guardant Health, Inc. | Helmy Eltoukhy Co-Chief Executive Officer | $9.4M 90,565 shares | -4% | |
| 75Notable | Guardant Health, Inc. | Darya Chudova Chief Technology Officer | $2.4M 22,935 shares | -106% | |
| 46Moderate | Guardant Health, Inc. | Medina Manuel Hidalgo director | $131k 1,250 shares | -61% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.